Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | The important role of bispecific antibodies in the future treatment of R/R DLBCL

Umberto Vitolo • 26 Sep 2022

SOHO 2022

Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Epcoritamab Glofitamab Lenalidomide Tafasitamab

In this video, Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, briefly discusses the need to improve treatment approaches for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of bispecific antibodies and their potential role in the DLBCL treatment armamentarium. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL

Umberto Vitolo • 10 Dec 2023

Rituximab ± lenalidomide as maintenance therapy in elderly patients with R/R FL

Umberto Vitolo • 10 Dec 2023

Bispecific antibodies in NHL: current insights and ongoing studies

Umberto Vitolo • 15 Jun 2023

The current state of treatment for limited-stage DLBCL

Umberto Vitolo • 15 Jun 2023

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024